Skip to main content

Remote Job Finders (RJF)

Sarepta Therapeutics faces serious FDA action after news broke of a third patient death, the FDA gets a new top drug regulator in George Tidmarsh, a handful of new drugs get turned away from the market and pharma companies continue to commit billions to reshoring manufacturing.
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
Scroll to top